COMMUNIQUÉS West-GlobeNewswire

Devonian Healthcare Group Reports its First ever Revenues: Key Financial Results for Quarter Ended April 30th, 2018
18/07/2018
QUEBEC CITY, July 18, 2018 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. ( “Devonian” or the “Corporation” ) (TSX VENTURE:GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique [...]
Groupe Santé Devonian rapporte ses premiers revenus : Résultats Financiers clés pour le trimestre terminé le 30 avril 2018
18/07/2018
QUÉBEC, 18 juill. 2018 (GLOBE NEWSWIRE) -- Groupe Santé Devonian inc. ( « Devonian » ou la « Soci é t é » ) (TSX CROISSANCE:GSD), une société pharmaceutique botanique en stade avancé de développement axée sur l’ [...]
Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus
18/07/2018
LAVAL, Quebec, July 18, 2018 (GLOBE NEWSWIRE) -- Altasciences is pleased to have partnered with Xeris Pharmaceuticals, a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop [...]
Altasciences participe à un essai clinique sur le diabète sucré de type 1
18/07/2018
LAVAL, Québec, 18 juill. 2018 (GLOBE NEWSWIRE) -- Altasciences est heureuse d’avoir collaboré avec Xeris Pharmaceuticals, une entreprise pharmaceutique spécialisée qui utilise ses nouvelles plateformes technologiques de [...]
PositiveID Adds Listeria to Pathogens Detected by FireflyDX Onsite Detection Prototype
18/07/2018
FireflyDX prototype can also detect E. coli and other pathogens in minutes DELRAY BEACH, Fla., July 18, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation’s (“PositiveID” or “Company”) (OTC:PSID) ExcitePCR subsidiary today [...]
HMS Holdings Corp. To Report Second Quarter 2018 Financial and Operating Results
18/07/2018
IRVING, Texas, July 18, 2018 (GLOBE NEWSWIRE) -- HMS Holdings Corp. (Nasdaq:HMSY) today announced it will report second quarter 2018 financial and operating results at 7:30 am CT / 8:30 am ET on Friday, August 3, 2018. [...]
Hemostemix Announces First U.S. Patients Treated in Phase II Clinical Trial
18/07/2018
CALGARY, Alberta, July 18, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM) is pleased to announce that it has treated three additional patients including its first two [...]
Spectral Announces Successful Manufacturing Audit of Toray by the US FDA
18/07/2018
TORONTO, July 18, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a [...]
Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
18/07/2018
33% Overall Response Rate Observed in DLBCL Patient Cohort MADISON, Wis., July 18, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, [...]
Taconic Biosciences and Cyagen Biosciences Announce Strategic Partnership
18/07/2018
RENSSELAER, N.Y., July 18, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences and Cyagen Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a [...]
FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
18/07/2018
The Prescription Drug User Fee Act (PDUFA) Target Action Date is January 18, 2019 MORRIS PLAINS, N.J., July 18, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading [...]
Pediapharm Announces Annual Audited Financial Results – 61% Annual Revenue Growth and 11th Consecutive Year-over-year Quarterly Growth
18/07/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTRÉAL, July 18, 2018 (GLOBE NEWSWIRE) -- Pediapharm Inc. (the “Company” or "Pediapharm") (TSX VENTURE:PDP) (OTCQB:PDDPF) is [...]
Pediapharm annonce ses résultats financiers audités annuels - hausse annuelle de 61% des revenus et 11e trimestre consécutif de croissance d’un exercice à l’autre
18/07/2018
N’EST PAS DESTINÉ À LA DISTRIBUTION AUX AGENCES DE PRESSE AMÉRICAINES NI À LA DIFFUSION AUX ÉTATS-UNIS MONTRÉAL, 18 juill. 2018 (GLOBE NEWSWIRE) -- Pediapharm inc. (la « Société » ou « Pediapharm ») (TSX CROISSANCE:PDP [...]
Inovalon Announces Second Quarter 2018 Earnings Conference Call
18/07/2018
BOWIE, Md., July 18, 2018 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq:INOV), a leading technology company providing advanced, cloud-based platforms empowering data-driven healthcare, today announced that it will hold a [...]
Precipio Announces 213% Year-over-Year Revenue Growth in Preliminary Q2-2018 Results
18/07/2018
Third consecutive quarter of triple-digit YoY Quarterly growth NEW HAVEN, Conn., July 18, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced preliminary second [...]
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
18/07/2018
Broad clinical program to include three studies expected to begin in the third quarter of calendar year 2018 in addition to the now fully enrolled Phase 1b/2a trial of adults with DEE Two rare disorders, CDKL5 [...]
Eloxx Pharmaceuticals To Present at the 38th Annual Canaccord Genuity Growth Conference
18/07/2018
WALTHAM, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic [...]
Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia
18/07/2018
HOUSTON, July 18, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of [...]
Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)
18/07/2018
Ongoing Alzheimer’s disease research programs target possible causes of the disease through multiple modalities Data to be presented from Alzheimer’s disease clinical development portfolio including aducanumab, [...]

Pages